Ironwood Pharmaceuticals (IRWD) Total Current Liabilities (2010 - 2026)

Ironwood Pharmaceuticals has disclosed Total Current Liabilities across 17 years of filings, most recently posting $236.3 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $236.3 million, up 391.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $236.3 million (up 391.31% YoY), and the FY2025 annual result was $242.2 million, up 523.53% from the prior year.
• Total Current Liabilities came in at $236.3 million for Q1 2026 at Ironwood Pharmaceuticals, down from $242.2 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $305.4 million in Q2 2023 to a low of $23.3 million in Q2 2022.
• The 5-year median for Total Current Liabilities is $147.4 million (2022), against an average of $146.9 million.
• Across the five-year window, Total Current Liabilities surged 1210.8% in 2023 and slumped 85.93% in 2024, its largest moves.
• Ironwood Pharmaceuticals' Total Current Liabilities stood at $25.5 million in 2022, then surged by 981.69% to $276.1 million in 2023, then plunged by 85.93% to $38.8 million in 2024, then soared by 523.53% to $242.2 million in 2025, then fell by 2.44% to $236.3 million in 2026.
• The last three Total Current Liabilities figures came in at $236.3 million (Q1 2026), $242.2 million (Q4 2025), and $242.5 million (Q3 2025), per Business Quant data.